Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"PharmaLogic","sponsor":"Viewpoint Molecular Targeting","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Perspective Therapeutics And Pharmalogic Announce Collaboration For The Development And Production Of Theranostics For Cancer Care","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"PharmaLogic","sponsor":"Nusano","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nusano and PharmaLogic Announce Collaboration to Enable Next Generation Radiotherapeutics Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"PharmaLogic","sponsor":"UPMC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UPMC and PharmaLogic Partner to Develop Novel Radiopharmaceuticals at New Facility in Pittsburgh","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"PharmaLogic","sponsor":"ARTBIO","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ARTBIO and PharmaLogic Announce Supply Agreement for Lead-212 based Therapeutic Candidate AB001 for New York and Surrounding States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by PharmaLogic

    Menu

    PharmaLogic

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              PharmaLogic

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ARTBIO and PharmaLogic Announce Supply Agreement for Lead-212 based Therapeutic Candidate AB001 for New York and Surrounding States

              Details:

              Under the agreement, PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 (212Pb-NG001), using ARTBIO's proprietary AlphaDirect™ 212Pb isolation technology.

              Lead Product(s): 212Pb-NG001

              Therapeutic Area: Oncology Product Name: AB001

              Highest Development Status: Phase I Product Type: Peptide

              Partner/Sponsor/Collaborator: ARTBIO

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement January 12, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PharmaLogic

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              UPMC and PharmaLogic Partner to Develop Novel Radiopharmaceuticals at New Facility in Pittsburgh

              Details:

              The collaboration aims to facilitate the development of novel radiopharmaceuticals for the diagnosis and treatment of cancer, cardiovascular and other diseases.

              Lead Product(s): Radiopharmaceutical

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: UPMC

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration June 21, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PharmaLogic

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nusano and PharmaLogic Announce Collaboration to Enable Next Generation Radiotherapeutics Development

              Details:

              The two organizations will collaborate to advance the development of radiopharmaceuticals to accelerate new and emerging cancer diagnostics and treatments.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Undisclosed

              Recipient: Nusano

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 15, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PharmaLogic

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Perspective Therapeutics And Pharmalogic Announce Collaboration For The Development And Production Of Theranostics For Cancer Care

              Details:

              Under the terms of the agreement, PharmaLogic will produce and supply doses of theranostic candidates, VMT-01 and VMT-α-NET for use in Perspective’s early-stage clinical trials, for the diagnosis and treatment of metastatic melanoma and neuroendocrine tumors, respectively.

              Lead Product(s): VMT-01

              Therapeutic Area: Oncology Product Name: VMT-01

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Viewpoint Molecular Targeting

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement March 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY